GlassScriptPhysician profile
Sheevam Shah
NPI 1255787529
$486,304.03
in general payments reported to CMS, 2019-2025
32 companies · $202K in 2025
The $202K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $143 · 2021: $777 · 2022: $7,897 · 2023: $120K · 2024: $155K · 2025: $202K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $318K · Consulting Fee: $59K · Travel and Lodging: $45K · Honoraria: $25K · Food and Beverage: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,498 · Education: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $317,827.50 |
| Consulting Fee | $59,055.00 |
| Travel and Lodging | $44,684.75 |
| Honoraria | $25,208.11 |
| Food and Beverage | $22,857.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,498.00 |
| Education | $566.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124,672.96 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $101,731.76 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Ucb, INC. | $65,739.58 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $52,429.71 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $50,064.80 | 2023-2024 | Vtama |
| Organon LLC | $29,731.41 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $15,228.08 | 2019-2025 | |
| Janssen Biotech, INC. | $12,110.85 | 2021-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $9,043.58 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $7,374.32 | 2019-2025 | |
| Incyte Corporation | $6,293.87 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $4,682.83 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,065.80 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,328.12 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $985.30 | 2021-2025 | Adbry, Anzupgo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $655.05 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $517.14 | 2021-2025 | |
| Allergan, INC. | $394.81 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $231.97 | 2022-2025 | Cabtreo, Jublia, Siliq |
| Pfizer INC. | $216.49 | 2019-2023 | |
| Stryker Corporation | $169.72 | 2023 | Mako |
| Merz North America, INC. | $130.16 | 2019 | |
| Celgene Corporation | $91.00 | 2019 | |
| Almirall LLC | $78.95 | 2022-2025 | Klisyri |
| Eli Lilly and Company | $78.79 | 2025 | Ebglyss |
| Revance Therapeutics, INC. | $76.97 | 2024-2025 | Daxxify |
| Botanix Sb INC | $58.20 | 2025 | Sofdra |
| Epi Health, LLC | $49.32 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $23.69 | 2021 | |
| Sebela Pharmaceuticals INC. | $18.69 | 2022 | |
| Journey Medical Corporation | $16.30 | 2022 | |
| Dermira, INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheevam Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.